EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual Roles of Lactate in EGFR-TKI-Resistant Lung Cancer by Targeting GPR81 and MCT1

Ruishuang Ma iD, Xin Li, Shengping Gong, Xiaoqin Ge, Ting Zhu, Xiaoxu Ge, Lijuan Weng, Qingsong Tao, Jianxin Guo iD

Journal of Oncology · 12.12.2022 · 2022 · 1-7

DOI: 10.1155/2022/3425841 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Oncology, erschienen am 12.12.2022. Verfasst von Ruishuang Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy and Chemotherapy, Ningbo First Hospital, Ningbo, China. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Harbin Medical University Cancer Hospital, Beijing Medical Award Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lactate is critical in modeling tumor microenvironment causing chemotherapy resistance; however, the role of lactate in tyrosine kinase inhibitor (TKI) resistance has not been fully known. The aim of this study was to evaluate whether lactate could mediate TKI resistance through GPR81 and MCT1 in non-small-cell lung cancer (NSCLC). Here, we showed that lactate enhanced the cell viability and restrained erlotinib-induced apoptosis in PC9 and HCC827 cells. GPR81 and AKT expression were significantly increased with the addition of lactate, and siGPR81 reduced AKT expression resulting in a raised apoptosis rate with erlotinib treatment. Furthermore, we found that lactate also promoted MCT1 exposure, and inhibiting MCT1 with AZD3965 markedly impaired the glycolytic capacity. A significant increase of GPR81 and MCT1 expression was observed in insensitive tissues compared with sensitive ones by immunostaining in NSCLC patients. Our results indicate that lactate adopts dual strategies to promote TKI resistance in NSCLC, not only activating AKT signaling by GPR81, but also giving energy supply through MCT1-mediated input. Targeting GPR81 and MCT1 may provide new therapeutic modalities for TKI resistance in NSCLC.

Autor:innen und Institutionen

  • Department of Radiotherapy and Chemotherapy, Ningbo First Hospital, Ningbo, China.
  • Central Laboratory of the Medical Research Center, Ningbo First Hospital, Ningbo, China.
  • Department of Respiratory Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

ORCID-Profile: Ruishuang Ma, Jianxin Guo

Förderung

  • National Natural Science Foundation of China
  • Harbin Medical University Cancer Hospital
  • Beijing Medical Award Foundation
  • Ningbo Health Branding Subject Fund

Zitieren

APA

Ma, R., Li, X., Gong, S., Ge, X., Zhu, T., Ge, X., Weng, L., Tao, Q., & Guo, J. (2022). Dual Roles of Lactate in EGFR-TKI-Resistant Lung Cancer by Targeting GPR81 and MCT1. Journal of Oncology, 2022, 1-7. https://doi.org/10.1155/2022/3425841

Vancouver

Ma R, Li X, Gong S, Ge X, Zhu T, Ge X, et al. Dual Roles of Lactate in EGFR-TKI-Resistant Lung Cancer by Targeting GPR81 and MCT1. Journal of Oncology. 2022;2022:1-7. doi:10.1155/2022/3425841

BibTeX
@article{Ma2022,
  author = {Ma, Ruishuang and Li, Xin and Gong, Shengping and Ge, Xiaoqin and Zhu, Ting and Ge, Xiaoxu and Weng, Lijuan and Tao, Qingsong and Guo, Jianxin},
  title = {Dual Roles of Lactate in EGFR-TKI-Resistant Lung Cancer by Targeting GPR81 and MCT1},
  journal = {Journal of Oncology},
  year = {2022},
  volume = {2022},
  pages = {1--7},
  doi = {10.1155/2022/3425841}
}
Kostenlos starten →